Strut Health Review: Real Compounding Accreditation and Only Nine Complaints — Undone by Two Words: 'Generic Zepbound'

What Is Strut Health?

Strut Health, LLC, trading as Strut and described on its site as 'a Partex.AI Consumer Health Company', operates from 701 Commerce St, Dallas, Texas, with a BBB file opened in August 2021. It was founded by Simal Patel, MD, and sells pharmacy-compounded treatments across weight loss, hair loss and hormones — semaglutide, tirzepatide, finasteride, dutasteride and oral sermorelin.

On credentials it is genuinely one of the better-documented companies we have reviewed. It states LegitScript certification, HIPAA compliance, and — most importantly — PCAB accreditation and an ACHC-accredited compounding pharmacy. PCAB is the recognised third-party accreditation for compounding quality, and it is a meaningfully higher standard than the unnamed, unaccredited arrangements common across this market. Its BBB profile shows a B+ rating with only nine complaints filed, which is a fraction of what comparable providers carry.

Pricing is month-to-month with no lock-in, which is a real advantage in a market full of prepaid annual bundles. Independent listings put oral semaglutide lozenges at $99 to $149 a month and injectables at $149 to $289. The catch is that none of this appears on the site — you must start a consultation to see what you will pay, which is the least transparent part of the model.

And then there is the FDA. On 20 February 2026 the agency issued Strut warning letter 721448, having reviewed its website in December 2025. The findings are set out in full below, and one of them is unusually blunt.

Treatments & Pricing

Prices come from independent listings as at 6 August 2026, because Strut does not publish them — its site requires you to begin a consultation before revealing cost. That is the single most avoidable weakness here, and it is reflected in the complaint record, where pricing clarity and unexpected cost increases are the leading theme. Billing is month to month with no lock-in, which is genuinely good. Note that the oral lozenge at $99 is the cheapest entry point and also the format with the least evidence behind it — see below.

Compounding Accreditation — and the FDA Warning Letter

Everything Strut sells in the weight-loss category is compounded, not brand-name. Compounded medications are not FDA-approved and have not been reviewed by the FDA for safety, efficacy or manufacturing quality.

Where Strut is genuinely better than most: its compounding is PCAB accredited through ACHC. PCAB accreditation involves independent audit against compounding standards and is the recognised quality mark in this space. Most providers we have reviewed this month either use unnamed 503A pharmacies or decline to say anything at all about accreditation. Strut naming a real, audited standard is a substantive difference in the assurance you have about what is in the vial.

Where it is worse: on 20 February 2026 the FDA issued warning letter 721448 to Strut Health, LLC dba Strut, having reviewed the website in December 2025. The agency found the compounded semaglutide and tirzepatide products misbranded under sections 502(a) and 502(bb) of the FDCA on two grounds. First, that the pictured product labels identified 'Strut', 'suggesting Strut is the compounder of those drugs when in fact it is not'. Second, and more seriously, it cited website claims including 'Generic Zepbound, Mounjaro' and statements that semaglutide and tirzepatide are 'the active ingredient in the brand medications', concluding: 'Your claims imply that your products have been FDA-approved or otherwise evaluated for safety and effectiveness when they have not.'

The phrase 'Generic Zepbound, Mounjaro' deserves singling out, because it is not a grey area. A generic drug in the United States is an FDA-approved product that has demonstrated bioequivalence to a reference medicine through an abbreviated new drug application. No generic Zepbound or Mounjaro exists. Describing a compounded preparation as a generic of a branded drug is not aggressive marketing — it is a description of a regulatory status the product does not have, and it is the kind of claim that leads patients to believe they are buying an equivalent medicine when they are not.

The FDA gave fifteen working days to respond. We report the letter because it is a public regulatory document about claims a buyer would rely on; it is not an allegation by a competitor.

The Consultation Process

Eligibility

• •Eligibility is determined by a licensed physician reviewing your online visit. No lab requirement is described and no specific BMI threshold is published on the pages we reviewed.
• •States served are not published. Confirm before starting a consultation.
• •GLP-1 medicines are contraindicated in people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2, and must not be used in pregnancy or while trying to conceive.
• •Clinician judgement is required for anyone with a history of pancreatitis, gallbladder disease, severe gastrointestinal disease including gastroparesis, or diabetic retinopathy.
• •Common side effects are gastrointestinal — nausea, vomiting, diarrhoea, constipation and reflux — usually worst after a dose increase. Less common but serious risks include pancreatitis, gallbladder disease and dehydration-related kidney injury.
• •Finasteride and dutasteride are for men only and must not be handled by anyone pregnant or who may become pregnant. Both can cause sexual side effects that persist after stopping in a minority of users, and both lower PSA readings — tell any clinician ordering a PSA test that you take them. Dutasteride for hair loss is an off-label use.
• •Oral sermorelin acts on the growth hormone axis, has no FDA approval for adult body composition or recovery use, and warrants real caution in anyone with a history of cancer.

Physicians, Testing & Compounding Pharmacy

Shipping & Support Services

Free shipping is included with treatment. Order-fulfilment problems relating to test kits appear in the complaint record, though medication delivery is not a dominant theme.

• •PCAB and ACHC-accredited compounding pharmacy — a real audited quality standard
• •LegitScript certified and HIPAA compliant
• •Founded by a physician, Simal Patel, MD
• •B+ BBB rating with only nine complaints on file
• •Month-to-month billing with no lock-in or prepaid bundles
• •Free shipping included
• •Broad range across weight loss, hair loss and hormones
• •Oral lozenge option for people who will not inject
• •Operating since at least 2021

Fees, Cancellation & Refunds

Insurance & HSA/FSA

Pros & Cons

Who Strut Health May Be Best For

• •People who prioritise compounding quality assurance and want a PCAB-accredited pharmacy behind their medication
• •Anyone who wants month-to-month billing rather than a prepaid annual bundle
• •Patients who will get their full price in writing before agreeing to anything
• •People wanting hair loss and weight treatment from one provider with genuine accreditation

Limitations

• •The 'Generic Zepbound, Mounjaro' claim is the reason this rates as it does, and it deserves to be understood rather than skimmed. In US drug law a generic is a specific thing: an FDA-approved product that has demonstrated bioequivalence to a reference medicine through an abbreviated new drug application. There is no generic Zepbound and no generic Mounjaro. Calling a compounded preparation a generic of either tells a patient they are buying a regulatory equivalent when they are buying something the FDA has never reviewed. That is materially more misleading than the 'same active ingredient' framing the agency has objected to elsewhere.
• •It is genuinely frustrating because the underlying operation looks better than most. PCAB and ACHC accreditation is a real, audited compounding standard that almost none of Strut's competitors can claim, and nine BBB complaints against a company trading since 2021 is a remarkably clean record next to the hundreds carried by others in this roundup. A company doing the hard part well should not need to describe its product as a generic.
• •Not publishing prices is the second self-inflicted problem. Requiring a consultation before revealing cost is exactly the design that produces the complaint theme Strut actually has — pricing clarity and unexpected increases. Competitors that publish a price list generate fewer of those disputes because there is nothing to be surprised by.
• •The oral lozenge is the item we would avoid. Semaglutide absorbs poorly across mucosal surfaces, the one FDA-approved oral version requires a specific absorption-enhancer technology to work at all, and no compounded lozenge has published data showing meaningful systemic exposure. At $99 it is the cheapest thing on the menu and probably the least likely to do anything.
• •In fairness, the FDA letter concerns marketing claims rather than manufacturing or patient harm, the company has a fifteen-working-day response obligation it may well have met, and dozens of companies received similar letters in the same February 2026 action. But this one contained the starkest claim of any we examined, and the fix — deleting one word — was always available.

Alternatives to Consider

Frequently Asked Questions

Our Verdict

Strut Health is the most frustrating review in this batch, because the hard parts are done well. PCAB and ACHC accreditation for its compounding is a genuine, independently audited quality standard that almost none of its competitors can claim, and it addresses the single biggest unknown in compounded medicine — whether what is in the vial matches what is on the label. Nine BBB complaints against a company trading since 2021, with a B+ rating, is a strikingly clean record next to the hundreds carried by others here. Month-to-month billing with no lock-in and free shipping are both the right choices.

Then the marketing gives it away. On 20 February 2026 the FDA wrote to Strut finding its compounded semaglutide and tirzepatide misbranded — that its own name on pictured labels implied it compounded drugs it does not compound, and that its website claims implied FDA approval that does not exist. Among those claims was 'Generic Zepbound, Mounjaro'. There is no generic Zepbound. There is no generic Mounjaro. Telling a patient otherwise says their compounded preparation carries a regulatory status that would require FDA approval and demonstrated bioequivalence, and it does not.

Compounding this is the refusal to publish prices. Requiring a consultation before revealing cost is precisely what generates Strut's actual complaint theme — pricing clarity and unexpected increases — and it is entirely avoidable.

We rate Strut Health 2.9 out of 5. Better compounding assurance than nearly anyone in this market, wrapped in claims the FDA has formally objected to and pricing it will not show you. If the PCAB accreditation is what draws you, get your full price in writing before agreeing to anything, skip the oral lozenge, and understand exactly what you are buying — a compounded preparation, not a generic. If you would rather have published pricing and a clean regulatory record, CoreAge Rx and CallonDoc are the comparisons to make.

This review is informational only and is not medical advice. Compounded GLP-1s are not FDA-approved and have not been evaluated for safety, efficacy or quality. Speak to a licensed clinician about whether treatment is appropriate for you before starting, changing or stopping any medication.